|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 54.72 CNY | +0.18% |
|
-7.49% | -19.61% |
Business description: Gan & Lee Pharmaceuticals.
Number of employees: 5,309
Sales by Activity: Gan & Lee Pharmaceuticals.
| Fiscal Period: December | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) | 2025 (CNY) |
|---|---|---|---|---|---|
Development, Production and Sales of Insulin and Related Products | 3.61B | 1.71B | 2.61B | 3.05B | 4.05B |
Geographical breakdown of sales: Gan & Lee Pharmaceuticals.
| Fiscal Period: December | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) | 2025 (CNY) |
|---|---|---|---|---|---|
China | 3.36B | 1.44B | 2.18B | 2.52B | 3.51B |
International | 256M | 276M | 426M | 528M | 539M |
Executive Committee: Gan & Lee Pharmaceuticals.
| Manager | Title | Age | Since |
|---|---|---|---|
Wei Chen
CEO | Chief Executive Officer | 46 | 29/05/2025 |
Qi Wang
DFI | Director of Finance/CFO | 44 | 08/03/2026 |
Ting Jia
CTO | Chief Tech/Sci/R&D Officer | - | 08/03/2026 |
Wei Qiang Song
PRN | Corporate Officer/Principal | 44 | 31/12/2004 |
Kai Du
CEO | Chief Executive Officer | 49 | 19/07/2020 |
Composition of the Board of Directors: Gan & Lee Pharmaceuticals.
| Director | Title | Age | Since |
|---|---|---|---|
Fu Ming Xu
BRD | Director/Board Member | 41 | 16/11/2025 |
Zhong Ru Gan
CHM | Chairman | 78 | 16/06/1998 |
Kai Du
BRD | Director/Board Member | 49 | 31/12/2009 |
Wei Qiang Song
BRD | Director/Board Member | 44 | 14/09/2015 |
Jiao Jiao
BRD | Director/Board Member | 38 | 17/03/2021 |
Hong Pin Du
BRD | Director/Board Member | 53 | 19/05/2025 |
Wei Chen
CHM | Chairman | 46 | 29/05/2025 |
Zeng Yi Chang
BRD | Director/Board Member | 61 | 18/05/2022 |
Company details: Gan & Lee Pharmaceuticals.
Biopharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.18% | -7.49% | +7.50% | +49.51% | 4.78B | |
| +0.10% | -12.87% | +5.66% | -16.96% | 64.13B | |
| +1.53% | -0.25% | +48.04% | +173.20% | 51.84B | |
| -2.89% | +34.60% | +34.60% | +34.60% | 41.28B | |
| -0.22% | -0.32% | -59.65% | -67.95% | 33.94B | |
| -0.70% | -4.41% | +47.22% | -38.23% | 28.13B | |
| -4.97% | -14.17% | +73.25% | -63.78% | 18.14B | |
| +0.43% | -3.56% | +49.82% | +50.39% | 19.1B | |
| -0.75% | -8.79% | +43.58% | +104.38% | 17.72B | |
| +0.18% | -0.36% | +40.79% | +83.00% | 15.96B | |
| Average | -0.12% | -5.91% | +29.08% | +30.81% | 29.5B | |
| Weighted average by Cap. | -0.10% | -6.15% | +24.83% | +31.03% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 603087 Stock
- Company Gan & Lee Pharmaceuticals.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition